Teva accused of “pay for delay” deal with Cephalon.
Luxturna granted six-month priority review by FDA.
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
Solution will let patients access, add to and electronically share their medical information.
Soriot to host results announcement as usual
Proposals fall short of ambitions of Accelerated Access Review.
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.